Bristol Myers
As seen in:
AU Investing,
Investing Canada,
Investing ZA,
Investing.com,
Morningstar,
CityAM,
RTT News,
HT Syndication,
BizToc,
DeepNewz
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bristol Myers
Page 15
CITYAM.COM THURSDAY 6 AUGUST 2026 | OPINION | 15 WE WANT TO HEAR YOUR VIEWS E: opinion@cityam.com COMMENT AT: cityam.com/opinion LETTERS IS IT EVER OK TO WEAR SHORTS TO THE OFFICE? Atrazeneca needs a brand strategy [RE: Astrazeneca share price tumbles on $400bn megamerger talks, 03 Aug] Astrazeneca’s tumbling share price captures a familiar anxiety around M&A deals. One that signals a lack of clear brand direction. The six per cent fall is the market questioning identity.
Bristol Myers, Takeda to pool data for AI-based drug discovery
By Sneha S K (Reuters) -, and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development. The companies are joining a consortium that includes and , and will contribute data from several thousand experimentally determined protein–small molecule structures to train an AI model called OpenFold3, life sciences company Apheris said on Wednesday.
Bristol Myers and SystImmune’s lung cancer drug gets FDA boost
Investing.com -- Bristol Myers (NYSE:) Squibb and SystImmune have received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for their experimental drug iza-bren, aimed at treating advanced EGFR-mutant lung cancer. The designation specifically targets patients with EGFR exon 19 or 21 mutations whose disease has progressed after treatment with EGFR tyrosine kinase inhibitors (TKI) and platinum-based chemotherapy.
Bristol Myers, Bain Capital form new company to develop immunology drugs
(Reuters) -Drugmaker Bristol Myers (NYSE:) Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain’s $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials.
BizToc
Market Summary US markets retreated early amid tariff and Fed chair firing jitters but recovered as strong earnings from tech giants and semiconductor leaders like TSMC and Meta bolstered optimism. The S&P 500 and Nasdaq edged towards record highs despite ongoing geopolitical tensions and tariff-driven inflation concerns. Walmart Shifts Pricing Amid Trump Tariff Impact...
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Published 07/17/2025, 07:22 AM Updated 07/17/2025, 07:26 AM Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients (Reuters) -US drugmakers Bristol Myers (NYSE:) and Pfizer (NYSE:) said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.
Zydus Lifesciences Acquires Agenus’ California Facilities, Licenses Cancer Drugs in $141 Million Deal; Agenus Shares Rise 24%
Daily market recaps with key events, stock movements, and global influences 9 posts • GPT (4.1 mini) Updated Jun 3, 2025, 07:15 PM Zydus Lifesciences has entered into a strategic agreement with US biotech firm Agenus, acquiring its biologics manufacturing facilities in Emeryville and Berkeley, California. The deal includes an upfront payment of $75 million, with potential milestone payments of up to $50 million, totaling $125 million.
Merck (MRK) Held Talks to Acquire MoonLake (MLTX) for Over $3 Billion; Shares Surge 23%
13 posts • GPT (4.1) Updated Jun 3, 2025, 08:11 PM Merck & Co. (MRK) has held talks to acquire Swiss biotechnology company MoonLake Immunotherapeutics (MLTX) in a deal valued at more than $3 billion, according to multiple reports. The U.S. pharmaceutical company submitted a nonbinding offer for MoonLake earlier this year, representing a premium to MoonLake's $2.6 billion market value at the time.
Zydus Lifesciences Acquires Agenus US Facilities in $125 Million Deal, Expands Cancer Immunotherapy with Botensilimab, Balstilimab
5 posts • GPT (4.1 mini) Published Jun 3, 2025, 01:07 PM Glenmark Pharma's biotechnology subsidiary, Ichnos Glenmark Innovation (IGI), announced positive results from an early-stage global study of its investigational drug targeting relapsed or refractory multiple myeloma, a blood cancer. Meanwhile, Medicamen Biotech received approval from the US Food and Drug Administration (FDA) for its Bortezomib Injection, a treatment used for multiple myeloma.
Merck Holds Talks to Acquire Swiss Biotech MoonLake Immunotherapeutics for Over $3 Billion; Stock Rises 15%-25% After Hours
7 posts • GPT (4.1 mini) Published Jun 2, 2025, 11:45 PM Merck has engaged in discussions to acquire Swiss biotechnology company MoonLake Immunotherapeutics for a price exceeding $3 billion. The talks have influenced market activity, with MoonLake's stock (ticker $MLTX) rising between 15% and 25% in after-hours trading following the news.
Sanofi to Acquire Blueprint Medicines for $129/Share, Up to $9.5 Billion; Ayvakit Added, Deal Closes Q3 2025
56 posts • GPT (4.1) Updated Jun 2, 2025, 05:30 PM Sanofi has agreed to acquire Blueprint Medicines Corporation, a U.S.-based biopharmaceutical company, for up to $9.5 billion. The deal includes an upfront cash payment of $129 per share, valuing Blueprint at approximately $9.1 billion, with additional non-tradeable contingent value rights (CVRs) of up to $6 per share tied to $2 and $4 milestones for the experimental drug BLU-808.
Sanofi to Acquire Blueprint Medicines for $129/Share, Deal Valued Up to $9.5 Billion With 27% Premium
40 posts • GPT (4.1) Updated Jun 2, 2025, 12:19 PM Sanofi SA has agreed to acquire Blueprint Medicines Corp. for $129 per share in cash, valuing the U.S.-based biopharmaceutical company at approximately $9.1 billion in equity value. The offer represents a 27% premium to Blueprint's closing price on Friday.
News Highlights: Top Global Markets News of the Day - Friday at 3 PM ET
Dow Rises More Than 700 Points U.S. stocks gained in the wake of more earnings and the Federal Reserve's preferred inflation gauge meeting economists' expectations. U.S. Inflation Data Keeps Door Open For September Interest Rate Cut Excluding volatile food and energy prices, PCE inflation rose 2.6%, the same as in May. The data keep alive prospects of interest rates declining later this year.
News Highlights: Top Global Markets News of the Day - Friday at 1 PM ET
Dow Rises More Than 700 Points U.S. stocks gained in the wake of more earnings and the Federal Reserve's preferred inflation gauge meeting economists' expectations. U.S. Inflation Data Keeps Door Open For September Interest Rate Cut Excluding volatile food and energy prices, PCE inflation rose 2.6%, the same as in May. The data keep alive prospects of interest rates declining later this year.
News Highlights: Top Global Markets News of the Day - Friday at 11 AM ET
Stocks Rise After Tame Inflation Data U.S. stocks gained in the wake of more earnings and the Federal Reserve's preferred inflation gauge meeting economists' expectations. U.S. Inflation Data Keeps Door Open For September Interest Rate Cut Excluding volatile food and energy prices, PCE inflation rose 2.6%, the same as in May. The data keep alive prospects of interest rates declining later this year.
News Highlights: Top Global Markets News of the Day - Friday at 7 AM ET
Stock Futures Rise as Chip Shares Rally Stock futures were higher as investors await the latest batch of earnings and the Fed's preferred inflation gauge. PCE to affirm inflation is slowing - but watch out for revisions The most critical inflation gauge in the U.S. is likely to affirm price increases are slowing, but the June report might also contain a bit of unwelcome news.
News Highlights: Top Global Markets News of the Day - Friday at 5 AM ET
PCE to affirm inflation is slowing - but watch out for revisions The most critical inflation gauge in the U.S. is likely to affirm price increases are slowing, but the June report might also contain a bit of unwelcome news. The New Threat to the Chip Industry: Worker Unrest With the industry growing in importance and investment pouring in, workers are demanding greater pay and benefits.
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
By Brendan Pierson (Reuters) - A judge in Hawaii on Tuesday ordered Bristol Myers (NYSE:) Squibb and Sanofi (NASDAQ:) to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford (NYSE:), of Hawaii's First Circuit Court, follows a non-jury trial held last fall.
Bristol-Myers's Abecma Receives CHMP Recommendation For Market Authorization
Bristol-Myers Squibb Company (BMY) on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma (idecabtagene vicleucel; ide-cel).
Bristol Myers Squibb Completes Acquisition Of Mirati For Upto $5.8 Bln Original
Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) announced on Tuesday that it has completed the acquisition of Mirati Therapeutics, Inc. (MRTX), a commercial-stage biotechnology company, in a deal worth up to $5.8 billion. The acquisition will bring in Mirati's commercialized lung cancer medicine KRAZATI and other clinical assets. The transaction will be accretive to the company's adjusted earnings per share by around $0.35 per share in 2024.
Bristol-Myers Squibb To Present At J.P. Morgan''s Healthcare Conference; Webcast At 10:30 AM ET
Bristol-Myers Squibb Co. (BMY) will present at J.P. Morgan''s 42nd Annual Healthcare Conference in San Francisco, California. The event is scheduled to begin at 10:30 AM ET on January 8, 2024. To access the live webcast, log on to http://investor.bms.com For comments and feedback contact: editorial@rttnews.com Biotech Stocks Facing FDA Decision In November 2023 Biotech Stocks Facing FDA Decision In October 2023 Biotech Stocks Facing FDA Decision in August 2023
Bristol-Myers Squibb To Present At Goldman Sachs Conference; Webcast At 11:00 AM ET Original
Bristol-Myers Squibb Co. (BMY) will participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference in New York City. The event is scheduled to begin at 11:00 AM ET on January 4, 2024. To access the live webcast, log on to https://www.bms.com For comments and feedback contact: editorial@rttnews.com Biotech Stocks Facing FDA Decision In November 2023 Biotech Stocks Facing FDA Decision In October 2023 Biotech Stocks Facing FDA Decision in August 2023
RayzeBio Stock More Than Doubles On Takeover By Bristol Myers
Shares of RayzeBio, Inc. (RYZB) surged over 100% on Tuesday morning after Bristol Myers Squibb (BMY) agreed to acquire RayzeBio for about $4.1 billion. RYZB is currently trading at $61.58, up $31.01 or 101.44%, on the Nasdaq. The stock opened its trading at $28.61 after closing Friday at $30.57. The stock has traded between $17.95 and $62.09 in the past 52-week period.
RayzeBio Stock More Than Doubles On Takeover By Bristol Myers
India, Dec. 26 -- Shares of RayzeBio, Inc. (RYZB) surged over 100% on Tuesday morning after Bristol Myers Squibb (BMY) agreed to acquire RayzeBio for about $4.1 billion. RYZB is currently trading at $61.58, up $31.01 or 101.44%, on the Nasdaq. The stock opened its trading at $28.61 after closing Friday at $30.57. The stock has traded between $17.95 and $62.09 in the past 52-week period.
Karuna To Be Acquired By Bristol Myers For $330 Per Share
Karuna Therapeutics Inc. (KRTX) has agreed to be acquired by Bristol Myers Squibb (BMY) for $330 per share in cash, for a total equity value of $14.0 billion. Karuna's lead asset, KarXT, proposed for the treatment of schizophrenia in adults, is under FDA review, with a decision on September 26, 2024. The transaction is expected to be dilutive to Bristol Myers Squibb's non-GAAP diluted earnings per share by approximately $0.30 in 2024. The stock closed yesterday's trading at $215.19, up 1.80%.
Training Industry Magazine - Spring 2023
SCIENCE OF LEARNING SRINI PILLAY, M.D. THE METAVERSE FOR WELL-BEING IN THE WORKPLACE Are you one of those people who has been ignoring the metaverse because it sounds like some trendy technology that has no relevance to you? Well, I'm writing this article to compel you to open your mind to the metaverse movement, because it's happening.
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
3/3 © Reuters. FILE PHOTO: A pharmacist holds a bottle of the drug Eliquis, made by Bristol Myers Squibb and Pfizer, at a pharmacy in Provo, Utah, U.S. January 9, 2020.
Bristol Myers, AbbVie plan to cut up to 360 California jobs
© Reuters. A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder (Reuters) - Drugmakers Bristol Myers (NYSE:) Squibb Co and AbbVie Inc (NYSE:) told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week. Bristol Myers plans to cut up to 261 jobs in two different locations in San Diego, according to the filings.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bristol
Contact Bristol, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack